Lunchtime ASX small cap wrap: who’s keeping up and who’s not
Link copied to
Here are the key ASX small cap winners and losers at 12.15pm AEST Thursday.
The ASX Small Ords index was up 21 points at 2829 by 1.25pm AEST.
Compumedics (ASX:CMP) soared 75 per cent to an intraday high of 72c this morning after announcing a deal with China-based health-check organisation Health 100.
The pair plan to commercialise Compumedic’s Somfit “sleep tracker” device in China.
Somfit tracks a user’s activities during the day as well as collecting “medical-grade data” at night to provide insights and help understand a person’s “sleep architecture”.
Under the deal, Health 100 will buy a million Somfit devices over two years, pending approval from China authorities.
Compumedics expects revenue to hit $133 million over that period.
The Compumedics guys sent out this picture below, featuring Victorian Premier Daniel Andrews (second from right) with Compumedics CEO Dr David Burton (far right).
It apparently shows a “ceremonial signing” of the deal but really we have no idea what’s going on.
In another big deal, Sino Gas & Energy (ASX:SEH) put on more than 20 per cent to an intraday high of 25.5c after a takeover offer.
US private equity investor Lone Star put forward a 25c a share cash bid for all of Sino Gas & Energy.
Earlier this week oil sector executives told Stockhead they were expecting a rash of deals to start. They said once that started, the whole sector would be re-rated upwards.
On Wednesday, Key Petroleum said a US investor had invested in one of its Queensland gas projects for a minimum of $5 million.
The Lone Star Fund X Acquisitions bid values Sino Gas at $528 million.
Melbourne-based cancer drug researcher Patrys (ASX: PAB) was heavily traded this morning after announcing further results from ongoing trial of its PAT‐DX1 drug candidate.
The shares gained more than 30 per cent to an intraday high of 5.4c with 55 million shares changing hands by noon.
Tests at the Yale School of Medicine confirmed the drug targeted tumour test “spheres” derived from human glioblastoma cancer stem cells, Patrys told investors.
The tests showed penetration into the centre of the tumour material and targeted cells inside as well as on the surface.
Patrys has previously shown its drug candidates can cross the blood brain barrier in a mouse model of glioblastoma.
“Confirmation that PAT‐DX1 targets and kills primary human glioblastoma stem cell tumour spheres in vitro is another exciting development,” said Patrys CEO Dr James Campbell.
Australian Mines (ASX:AUZ) continued to push forward after reporting positive cobalt results at its Thackaringa project in New South Wales earlier this week.
On Tuesday the stock gained 10 per cent to 9c in early trade.
Today it climbed another 14 per cent to 10.5c with 20 million shares traded.
Aus Mines told investors on Tuesday it had identified “three zones of elevated levels of cobalt” that were reportedly similar to that observed at surface over Cobalt Blue’s (ASX:COB) Pyrite Hill and Big Hill cobalt deposits.
Soil and surface sampling would continue with further results expected in the coming quarter ahead of a maiden drilling program.
Cancer drug maker Immutep (ASX:IMM) has also continued to win investor interest after announcing new data from a Phase I clinical trial earlier this week.
The shares rose 12 per cent to 3.7c with almost 16 million shares traded by 12.30pm AEST.
The trial is evaluating Immutep’s lead product eftilagimod alpha (or “efti”) in combination with another drug pembrolizumab in melanoma patients that have had a poor response or disease progression with pembrolizumab alone.
Here’s a snapshot of the best performing ASX small caps at 12.15pm AEST Thursday:
Centaurus Metals (ASX:CTM) fell back today after a big jump on Tuesday.
The stock was down 14 per cent to 1.2c today after hitting 1.7c on Tuesday.
Earlier this week Centaurus reported its first assays (or lab results) from a maiden drilling program at its Itapitanga nickel and cobalt project in Brazil.
Centaurus reported “the discovery of significant high‐grade nickel and cobalt mineralisation”.
Here’s a snapshot of the worst performing ASX small caps at 12.15pm AEST Thursday: